Here is the list in order of FDA approval date:
1. Dupixent – Additional use: Eosinophilic esophagitis (an allergic condition that causes inflammation of the esophagus)
2. Amtagvi – New medication: Advanced melanoma
3. Xolair – Additional use: Food allergies
4. Wegovy – Additional use: Cardiovascular risk reduction
5. Tryvio – New medication: High blood pressure
6. Nexletol – Additional use: High cholesterol
7. Winrevair – New medication: Pulmonary arterial hypertension
8. mRESVIA – New vaccine: RSV
9. Capvaxive – New vaccine: Pneumococcal disease
10. Wakix – Additional use: Pediatric narcolepsy
11. Ohtuvayre – New medication: COPD
12. Kisunla – New medication: Alzheimer’s disease
13. Voquezna – Additional use: Heartburn from non-erosive GERD (gastroesophageal reflux disease)
14. Zunveyl – New medication: Alzheimer’s disease
15. Yorvipath – New medication: Hypoparathyroidism (low levels of the parathyroid hormone)
16. Neffy – New medication: Severe allergic reactions
17. FluMist – Additional use: Self- or caregiver-administration
18. Cobenfy – New medication: Schizophrenia
19. Dupixent – Additional use: COPD
Some medications offer new treatments for common conditions, like Tryvio for high blood pressure and Nexletol for high cholesterol. Some newly approved medications are administered via injection, like Kisunla for Alzheimer’s and Dupixent.
Many of the newly approved drugs are nasal sprays, like FluMist, a nasal spray vaccine that helps prevent the flu, and Neffy, which is used to treat life-threatening allergic reactions.
In a disclaimer, GoodRx noted that the list was created by prioritizing “first-in-class medications and vaccines that are expected to have a significant impact on human health.”
“This was defined as either the number of lives touched or the expected degree of impact for future medication recipients,” the company wrote.
“We also prioritized medications with effectiveness or safety data that represent a notable advantage over other medications recommended by clinical treatment guidelines or mainstay medical organizations.”
